Fenton reaction-based nanomedicine in cancer chemodynamic and synergistic therapy
Source abstract
Abstract
Abstract The recently developed reactive oxygen species (ROS)-manipulated nanocatalytic medicine in cancer treatment based on the Fenton reaction, defined as chemodynamic therapy (CDT), has been extensively studied and got fast progress. However, the heterogeneity and complexity of tumors impair the oxidation efficiency of Fenton reaction to some degree. For this reason, various modified strategies, such as Fenton-like reaction, photo-enhanced Fenton reaction, and Fenton catalytic-enhanced synergistic therapy, are being explored to improve the efficiency of CDT and traditional therapeutic methods. In this review, the recent progress in the design and application of Fenton nanocatalysts that employ Fenton or modified Fenton reaction for CDT is highlighted. Then, the latest signs of improvement in Fenton catalysis-enhanced cancer synergistic therapy are systematically presented. Finally, the purpose of this review is also to provide a better understanding of Fenton's reaction in cancer treatment and to anticipate the obstacles and challenges in the future development of CDT-based nanocatalytic medicine and combined therapy.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Photocatalysis Techniques · Advanced Nanomaterials in Catalysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Cancer is a preventable disease that requires major lifestyle changes10.1007/s11095-008-9661-9 ↗
2. Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers10.1038/nature13187 ↗
3. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?10.1038/nrd2803 ↗
4. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis10.1038/nrm2256 ↗
5. Photodynamic therapy and anti-tumour immunity10.1038/nrc1894 ↗
6. Nano-Fenton reactors as a new class of oxidative stress amplifying anticancer therapeutic agents10.1021/acsami.5b12523 ↗
7. Singlet oxygen mediated iron-based Fenton-like catalysis under nanoconfinement10.1073/pnas.1819382116 ↗
8. Role of Reactive Oxygen Species (ROS) in therapeutics and drug resistance in cancer and bacteria10.1021/acs.jmedchem.6b01243 ↗
9. Strategies for enhancing the heterogeneous Fenton catalytic reactivity: a review10.1016/j.apcatb.2019.05.041 ↗
10. Cancer treatment through nanoparticle-facilitated fenton reaction10.1021/acsnano.8b07635 ↗
11. Reactive Oxygen Species (ROS)-based nanomedicine10.1021/acs.chemrev.8b00626 ↗
12. Cancer metabolism: current understanding and therapies10.1021/acs.chemrev.7b00775 ↗
13. Photodynamic therapy for prostate cancer—a review of current status and future promise10.1038/ncpuro1274 ↗
14. Reactive oxygen species generating systems meeting challenges of photodynamic cancer therapy10.1039/C6CS00271D ↗
15. Photodynamic therapy for cancer10.1038/nrc1071 ↗
16. Nanoparticles in sonodynamic therapy: state of the art review10.1039/C6RA06862F ↗
17. Imaging and photodynamic therapy: mechanisms, monitoring, and optimization10.1021/cr900300p ↗
18. Metal-organic-framework-derived carbon nanostructure augmented sonodynamic cancer therapy10.1002/adma.201800180 ↗
19. Tumor-selective catalytic nanosystem for activatable theranostics10.1039/C8CC03922D ↗
20. Precise nanomedicine for intelligent therapy of cancer10.1007/s11426-018-9397-5 ↗
21. Tumor microenvironment‐enabled nanotherapy10.1002/adhm.201701156 ↗
22. Nanocatalysts-augmented Fenton chemical reaction for nanocatalytic tumor therapy10.1016/j.biomaterials.2019.04.023 ↗
23. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized Fenton reaction10.1002/anie.201510031 ↗
24. Amplification of tumor oxidative stresses with liposomal fenton catalyst and glutathione inhibitor for enhanced cancer chemotherapy and radiotherapy10.1021/acs.nanolett.8b03905 ↗
25. Chemodynamic therapy: tumour microenvironment‐mediated Fenton and Fenton‐like reactions10.1002/anie.201805664 ↗
26. Effect of pH on Fenton and Fenton‐like oxidation10.1080/09593330802468848 ↗
27. Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro10.1126/science.2834821 ↗
28. Metal sulfides as excellent co-catalysts for H2O2 decomposition in advanced oxidation processes10.1016/j.chempr.2018.03.002 ↗
29. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues10.1038/nnano.2016.168 ↗
30. Chemistry of mesoporous organosilica in nanotechnology: molecularly organic-Inorganic hybridization into frameworks10.1002/adma.201505147 ↗
31. Nanoscale metal-organic frameworks for therapeutic, imaging, and sensing applications10.1002/adma.201707634 ↗
32. Cancer cell nucleus-targeting nanocomposites for advanced tumor therapeutics10.1039/C8CS00081F ↗
33. Nanoparticle-triggered in situ catalytic chemical reactions for tumour-specific therapy10.1039/C7CS00471K ↗
34. Tumor-selective catalytic nanomedicine by nanocatalyst delivery10.1038/s41467-017-00424-8 ↗
35. Nanotechnology for multimodal synergistic cancer therapy10.1021/acs.chemrev.7b00258 ↗
36. Reactive oxygen species–activatable liposomes regulating hypoxic tumor microenvironment for synergistic photo/chemodynamic therapies
37. Mild hyperthermia enhanced enzyme-mediate tumor cell chemodynamic therapy10.1021/acsami.9b08257 ↗
38. Sequential catalytic nanomedicine augments synergistic chemodrug and chemodynamic cancer therapy10.1039/C9NH00008A ↗
39. MnO2-disguised upconversion hybrid nanocomposite: an ideal architecture for tumor microenvironment-triggered UCL/MR bioimaging and enhanced chemodynamic therapy10.1021/acs.chemmater.9b00893 ↗
40. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology10.1158/0008-5472.CAN-12-4561 ↗
41. Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems10.1039/C5CS00798D ↗
42. Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials10.1002/smll.201303627 ↗
43. Tumor-specific expansion of oxidative stress by glutathione depletion and use of a Fenton nanoagent for enhanced chemodynamic therapy10.1021/acsami.9b09323 ↗
44. Rerouting engineered metal-dependent shapes of mesoporous silica nanocontainers to biodegradable Janus-type (sphero-ellipsoid) nanoreactors for chemodynamic therapy10.1016/j.cej.2019.03.272 ↗
45. The two faces of reactive oxygen species in cancer10.1146/annurev-cancerbio-041916-065808 ↗
46. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?10.1038/nrc3803 ↗
47. The phosphoinositide 3-kinase pathway10.1126/science.296.5573.1655 ↗
48. Switching Akt: from survival signaling to deadly response
49. Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways?10.1155/2011/792639 ↗
50. M.J. Morgan, Z.G. Liu, Crosstalk of reactive oxygen species and NF-κB signaling. 21 (2010) 103-115.10.1038/cr.2010.178 ↗
51. Mitochondria-derived ROS activate AMP-activated protein kinase (AMPK) indirectly10.1074/jbc.RA118.002579 ↗
52. Structure and mechanisms of ROS generation by NADPH oxidases10.1016/j.sbi.2019.03.001 ↗
53. ROS in cancer therapy: the bright side of the moon10.1038/s12276-020-0384-2 ↗
54. Signal transduction by reactive oxygen species10.1083/jcb.201102095 ↗
55. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors10.1021/acsnano.8b06201 ↗
56. Toxicity of iron and hydrogen peroxide: the Fenton reaction10.1016/0378-4274(95)03532-X ↗
57. Nanomaterial-induced ferroptosis for cancer specific therapy10.1016/j.ccr.2018.12.015 ↗
58. Multifunctional nanoplatform for photoacoustic imaging-guided combined therapy enhanced by CO induced ferroptosis10.1016/j.biomaterials.2019.01.026 ↗
59. Engineered bacterial bioreactor for tumor therapy via Fenton‐like reaction with localized H2O2 generation10.1002/adma.201808278 ↗
60. The role of iron and reactive oxygen species in cell death10.1038/nchembio.1416 ↗
61. Ferrous-cysteine–phosphotungstate nanoagent with neutral pH fenton reaction activity for enhanced cancer chemodynamic therapy10.1039/C8MH01176A ↗
62. MOF-mediated destruction of cancer using the cell’s own hydrogen peroxide10.1021/acsami.7b07981 ↗
63. Sulfosalicylic acid/Fe3+ based nanoscale coordination polymers for effective cancer therapy by the Fenton reaction: an inspiration for understanding the role of aspirin in the prevention of cancer10.1039/C9BM00799G ↗
64. Enhanced tumor-specific disulfiram chemotherapy by in situ Cu2+ chelation-initiated nontoxicity-to-toxicity transition10.1021/jacs.9b03503 ↗
65. Ce-doped ZnO (CexZn1−xO) becomes an efficient visible-light-sensitive photocatalyst by co-catalyst Cu2+ grafting10.1039/c1cp21514k ↗
66. Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase10.1126/science.284.5415.805 ↗
67. Advances in metal-induced oxidative stress and human disease10.1016/j.tox.2011.03.001 ↗
68. N-(2-hydroxypropyl) methacrylamide copolymers of a glutathione (GSH)-activated glyoxalase i inhibitor and DNA alkylating agent: synthesis, reaction kinetics with GSH, and in vitro antitumor activities10.1021/bc0499634 ↗
69. Glutathione and redox signaling in substance abuse10.1016/j.biopha.2014.06.001 ↗
70. Glutathione metabolism and its implications for health10.1093/jn/134.3.489 ↗
71. Self-assembled copper–amino acid nanoparticles for in situ glutathione “AND” H2O2 sequentially triggered chemodynamic therapy10.1021/jacs.8b08714 ↗
72. Synthesis of copper peroxide nanodots for H2O2 self-supplying chemodynamic therapy10.1021/jacs.9b03457 ↗
73. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy10.1002/anie.201712027 ↗
74. Mechanisms of the pH dependent generation of hydroxyl radicals and oxygen induced by Ag nanoparticles10.1016/j.biomaterials.2012.06.076 ↗
75. Cancer cell membrane camouflaged cascade bioreactor for cancer targeted starvation and photodynamic therapy10.1021/acsnano.7b02533 ↗
76. Hollow MnO2 as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses10.1038/s41467-017-01050-0 ↗
77. Smart nanoreactors for pH-responsive tumor homing, mitochondria-targeting, and enhanced photodynamic-immunotherapy of cancer10.1021/acs.nanolett.8b00040 ↗
78. Overcoming the Achilles' heel of photodynamic therapy10.1039/C6CS00616G ↗
79. Porphyrin–ferrocene conjugates for photodynamic and chemodynamic therapy10.1039/C8OB02391C ↗
80. Continuous O2-evolving MnFe2O4 nanoparticle-anchored mesoporous silica nanoparticles for efficient photodynamic therapy in hypoxic cancer10.1021/jacs.7b05559 ↗
81. Near‐infrared upconversion mesoporous cerium oxide hollow biophotocatalyst for concurrent pH‐/H2O2‐responsive O2‐evolving synergetic cancer therapy10.1002/adma.201704833 ↗
82. Factorial design analysis for COD removal from landfill leachate by photoassisted Fered-Fenton process10.1007/s11356-014-2790-2 ↗
83. Trends in the use of Fenton, electro-Fenton and photo-Fenton for the treatment of landfill leachate10.1016/j.wasman.2010.07.003 ↗
84. Lanthanide-doped luminescent nanoprobes: controlled synthesis, optical spectroscopy, and bioapplications10.1039/c3cs60060b ↗
85. Upconversion nanoparticles: design, nanochemistry, and applications in theranostics10.1021/cr400425h ↗
86. Upconversion nanoparticles in biological labeling, imaging, and therapy10.1039/c0an00144a ↗
87. In vivo photodynamic therapy using upconversion nanoparticles as remote-controlled nanotransducers10.1038/nm.2933 ↗
88. Near-infrared light induced in vivo photodynamic therapy of cancer based on upconversion nanoparticles10.1016/j.biomaterials.2011.05.007 ↗
89. Near infrared-assisted Fenton reaction for tumor-specific and mitochondrial DNA-targeted photochemotherapy10.1016/j.biomaterials.2017.06.035 ↗
90. Metal-organic frameworks join hands to create an anti-cancer nanoplatform based on 808 nm light driving up-conversion nanoparticles10.1016/j.cej.2018.03.101 ↗
91. Glucose oxidase-instructed multimodal synergistic cancer therapy10.1002/adma.201808325 ↗
92. Magnetic iron oxide nanoparticles/10-hydroxy camptothecin co-loaded nanogel for enhanced photothermal-chemo therapy10.1016/j.apmt.2018.11.008 ↗
93. Multifunctional MoO2-ICG nanoplatform for 808nm-mediated synergetic photodynamic/photothermal therapy10.1016/j.apmt.2019.03.008 ↗
94. A multifunctional PB@mSiO2–PEG/DOX nanoplatform for combined photothermal–chemotherapy of tumor10.1021/acsami.6b01147 ↗
95. Cisplatin is retained in the cochlea indefinitely following chemotherapy10.1038/s41467-017-01837-1 ↗
96. Designer vaccine nanodiscs for personalized cancer immunotherapy10.1038/nmat4822 ↗
97. Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy10.7150/thno.29431 ↗
98. Innovative strategies for hypoxic-tumor photodynamic therapy10.1002/anie.201805138 ↗
99. Ultrasmall Cu2‐xS nanodots for highly efficient photoacoustic imaging‐guided photothermal therapy10.1002/smll.201403249 ↗
100. Long‐range nanoparticle surface‐energy‐transfer ruler for monitoring photothermal therapy response10.1002/smll.201100591 ↗